糖尿病肾病组学标志物的研究进展  

Research progress on omics markers of diabetic kidney disease

作　　者：吕璐 李映 刘江涛 李哲(综述)[1,2,3,4] 马瑜瑾(审校) LYU Lu;LI Ying;LIU Jiangtao;LI Zhe;MA Yujin(College of Clinical Medicine,Henan University of Science and Technology,Luoyang,Henan 471003,China;Endocrinology and Metabolism Center,First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan 471003,China;Henan Key Laboratory of Rare Diseases,Luoyang,Henan 471003,China;Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine,Luoyang,Henan 471003,China;Department of Pharmacy,First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan 471003,China)

机构地区：[1]河南科技大学临床医学院,河南洛阳471003 [2]河南科技大学第一附属医院内分泌代谢中心,河南洛阳471003 [3]河南省罕见病重点实验室,河南洛阳471003 [4]河南省洛阳市临床多组学与转化医学重点实验室,河南洛阳471003 [5]河南科技大学第一附属医院药学部,河南洛阳471003

出　　处：《检验医学与临床》2025年第9期1290-1296,共7页Laboratory Medicine and Clinic

摘　　要：糖尿病肾病(DKD)是终末期肾脏病(ESRD)的首要病因。DKD的早期识别对疾病的早期评估、及时干预、改善预后至关重要。目前,DKD的主要诊断指标是估算肾小球滤过率(eGFR)和尿清蛋白/肌酐比值(UACR),然而这对于诊断早期肾脏功能改变及尿清蛋白正常的DKD存在严重不足。近几年,随着组学技术的发展,越来越多的DKD新型标志物被发现。该文从新的组学技术出发,分别从单组学、多组学联合、无创影像组学等方面,总结了DKD新型标志物的研究进展。该文最后讨论了新型组学技术及成果在临床应用中的优势与不足,并进一步探讨了它们在临床实践中用于诊断、治疗及预防DKD的可能性,为未来个性化精准医疗提供依据。Diabetes kidney disease(DKD)is the primary cause of end-stage kidney disease(ESRD).Early identification of DKD is crucial for early disease assessment,timely intervention and improves prognosis.Currently,the main diagnostic indexes for DKD are the estimated glomerular filtration rate(eGFR)and urinary albumin-to-creatinine ratio(UACR).However,these indexes have significant limitations in diagnosing early renal function changes and DKD with normal urinary albumin levels.In recent years,with the advancement of omics technology,an increasing number of novel markers for DKD have been discovered.This review summarizes the research progress of new markers for DKD from the perspectives of single omics,multi-omics integration,non-invasive imaging omics,based on new omics technologies.Finally,this article discusses the advantages and disadvantages of new omics technologies and their achievements in clinical applications,and further explores their potential for diagnosis,treatment,and prevention of DKD in clinical practice,providing the basis for personalized precision medicine in the future.

关 键 词：糖尿病肾病 标志物 组学 诊断 治疗 

分 类 号：R587.2[医药卫生—内分泌] R318.01[医药卫生—内科学]